Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M, Aizawa Y, Chuganji Y, Ishizuka H, Fujita Y, Aizawa R, Abe H, Matsuda T, Itou Y, Nakanishi H, Ushiyama H, Higuchi T, Fujimoto T, Endou H, Iga D, Ohta K, Kuroda H.
Tomimatsu M, et al. Among authors: abe h.
J Gastroenterol Hepatol. 2006 Jul;21(7):1177-83. doi: 10.1111/j.1440-1746.2006.04311.x.
J Gastroenterol Hepatol. 2006.
PMID: 16824072